The fact that this was associated to a potent immunosuppressive activity and that LOX-1 inhibition can block the suppressive activity of LOX-1 PMN-MDSCs could have a potential therapeutic application in NSCLC (94). Here, OLR1 is linked to non-small cell lung carcinoma.